BMS withdraws EU application for Ixempra in breast cancer
20 March 2009
Malini Guha
Please Login to read the full article.
20 March 2009
Malini Guha
malini.guha@informa.com
Bristol-Myers Squibb has withdrawn its EU marketing application for its novel chemotherapy agent Ixempra (ixabepilone) to treat locally advanced or metastatic breast cancer after failure of previous chemotherapy drugs.
In November, the
CHMP adopted a negative opinion, recommending the refusal...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Roche's T-DM1 (Herceptin-plus) shows early benefit in first-line metastatic breast cancer
- Eisai's Halaven stumbles at NICE efficacy hurdle
- AstraZeneca wins US approval of first rare thyroid cancer drug
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
